A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
Health myTomorrows Secures $29M to Fuel Global Expansion of Pre-Approval Therapy Access –Healthradar11. November 2025 What You Should Know: – myTomorrows, a health technology company that connects patients with all possible pre-approval treatments, today announced…
News The Sunrise Group Secures $29M to Scale Dreem Health NationwideHealthradar25. September 2025 What You Should Know: –Sunrise Group, a leader in sleep health technology, today announced a $29 million funding round to…
